Overview

A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis

Status:
RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

This is a, phase 1/2a trial, to assess the safety, tolerability, systemic exposure as well as preliminary efficacy following a single intra-articular injection of 3 dose levels of SYN321 in patients with symptomatic knee osteoarthritis (KOA).

Phase:

PHASE1

Details

Lead Sponsor:

Synartro AB

Collaborator:

CTC Clinical Trial Consultants AB